SL 401

Drug Profile

SL 401

Alternative Names: DT(388)IL3; DT388 IL3; DTIL3; SL-401

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Texas A&M University
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Dendritic cell inhibitors; Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I/II Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders
  • Preclinical Haematological malignancies; Hairy cell leukaemia
  • No development reported Chronic myeloid leukaemia; Lymphoma

Most Recent Events

  • 06 Jan 2017 Stemline Therapeutics announces intention to submit BLA to US FDA in 2H2017
  • 06 Dec 2016 Safety and efficacy results from the phase II trials in Acute myeloid leukaemia and Myeloproliferative disorders presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016 (9208402)
  • 05 Dec 2016 Safety and efficacy data from a phase II trial in Acute myeloid leukaemia (Blastic plasmacytoid dendritic cell neoplasm) presented at the 58th Annual Meeting of American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top